
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics is a clinical-stage precision medicine company with a strong pipeline of potential life-changing therapies in precision oncology and genetic disease. Their Dynamo platform integrates cutting-edge computational and experimental approaches, making them a leader in drug discovery. Recent data shows promising potential for their candidates in both front-line and later-line treatments, with good tolerability and potential to improve on negative psychological impacts associated with IV therapy. The company's well-balanced patient demographics and progress in their clinical trials demonstrate a strong potential for future success.
Bears say
Relay Therapeutics is currently undergoing clinical trials for various precision oncology and genetic disease targets, which presents inherent risks for the company's drug development process. Additionally, the company's potential for regulatory and commercial success is uncertain, and it may face competition from larger companies in the cancer therapeutic industry. Furthermore, the company is likely to seek additional equity financing, creating dilution risk for existing shareholders.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares